October 3, 2017
Ono Pharmaceutical and Seikagaku said on September 28 that they have commenced a PIIb clinical study of SI-613 for the treatment of enthesopathy in Japan. SI-613, an injectable formulation binding hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) by using...read more